CN103550236A - Compound taurine preparation - Google Patents
Compound taurine preparation Download PDFInfo
- Publication number
- CN103550236A CN103550236A CN201310534597.3A CN201310534597A CN103550236A CN 103550236 A CN103550236 A CN 103550236A CN 201310534597 A CN201310534597 A CN 201310534597A CN 103550236 A CN103550236 A CN 103550236A
- Authority
- CN
- China
- Prior art keywords
- preparation
- liver
- taurine
- compound
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a compound taurine preparation which is mainly prepared from taurine and glycyrrhetate. The preparation has definite curative effect on many types of hepatic injuries, has the characteristics of quick effect taking, short curative period, low cost, small side effect and the like, and brings good news to the patients.
Description
Technical field
The invention belongs to biomedicine field, be specifically related to a kind of compound taurine preparation.
Background technology
In China, the hepatopath who causes because of factors such as chemicals, pathogen or excessive consumptions of alcohol has exceeded ten million, and hepatitis is one of main illness of serious threat China people's health.Hepatitis is the general name of liver generation inflammatory lesion, in the clinical treatment of hepatitis, generally adopts Synthetic therapy, i.e. antiviral agents, immunostimulant and hepatoprotective partner treatment.Antiviral agents, immunostimulant focus on the virus of removing in body, and hepatoprotective focuses on the recovery of liver.Real at present effectively antiviral agents is very few, as anti-hepatic-B virus medicines such as lamivudine, famciclovirs, also cannot suppress virus completely.The generally acknowledged effective immunostimulant of anti-hepatitis virus is interferon at present, also cannot overcome viral knock-on problem.Therefore in the treatment of viral hepatitis, antiviral agents, immunostimulant and hepatoprotective are all very important, especially need hepatic in the treatment of the damaging hepatitis of chemical toxicant, so the market of hepatoprotective is huge.
At present, very active to the research of Chinese herbal medicine anti-liver injury both at home and abroad, the effective monomer that has Chinese herbal folk, Chinese herb compound and extract from Chinese herbal medicine of domestic research.
1. Chinese herbal folk
The people such as Wang Yaojun study and find that Cordyceps has liver-protective effect, can prevent hepatocyte spotty necrosis and focal necrosis, suppress the formation of liver pseudolobuli.The Radix Astragali can make rat liver fibrosis degree obviously reduce, and reduces I, III, the deposition of IV Collagen Type VI in liver.Radix Salviae Miltiorrhizae is a kind of up-and-coming anti-liver injury Chinese medicine, and its mechanism of action is many-sided, as improves microcirculation in liver, suppresses lipid peroxidation, protection hepatocyte, the collagen degradation of promotion deposition and heavily absorption etc.Radix Notoginseng has the effect of activating blood circulation to dissipate blood stasis, can suppress fibroblastic activity in liver, reduces the generation of collagen fiber.In addition, acting on of the anti-liver injury of the Chinese medicine such as Radix Glycyrrhizae, Poria, Fructus Schisandrae Chinensis, Radix Bupleuri, Flos Carthami, Herba Sedi, Herba Silybi mariani also obtained confirmation in experimentation.
2. Chinese herb compound
Except classical compound preparation, outside Herba Sidae Rhombifoliae soup, TAOHONG SIWU TANG etc., in conjunction with theory of Chinese medical science, effective single medicinal material reasonable combination, form new compound preparation, can improve the effect of anti-liver injury.Wang Baoen etc. form activating blood circulation to dissipate blood stasis prescription by Radix Salviae Miltiorrhizae, the Radix Astragali, Caulis Spatholobi, can obviously prevent CCl
4the formation of institute's liver fibrosis due regulating liver-QI sclerosis.The prescription being comprised of Radix Codonopsis, the Radix Astragali, Fructus Jujubae has the effect of righting tonify deficiency, can alleviate hepatocellular degeneration necrosis, suppresses the formation of hepatocyte proliferation of fibrous tissue and pseudolobuli, and liver cirrhosis is had to certain preventive and therapeutic effect.
3. the effective monomer extracting in Chinese herbal medicine
Have oleanolic acid and the Cucurbitacin B of early research pass through protection hepatocyte, reduce and stimulate, and indirectly suppress startup and the development of hepatic fibrosis.Glycyrrhizin can obviously suppress the formation of liver cirrhosis.The researchs such as Chen Zhong show that ligustrazine can obviously reduce the content of rat blood serum glutamate pyruvate transaminase, malonaldehyde, III procollagen type and hepatic tissue malonaldehyde, improve the activity of superoxide dismutase in hepatic tissue.Tetrandrine is a kind of bisbenzylisoquinoline alkaloid extracting from Radix Stephaniae Tetrandrae root piece, and the effect of its anti-liver injury is confirmed.Oxymatrine is a kind of alkaloid extracting from plant Radix Sophorae Tonkinensis, and chronic hepatitis C is had to good therapeutic effect, and cultured cell in vitro research finds that oxymatrine on rat liver Ito cell proliferation has inhibitory action.
Along with the continuous change of living standards of the people and life style, various Chinese medicine liver-protecting products arise at the historic moment, but majority all exists the shortcomings such as effect is unsatisfactory, does not have so far liver-protecting product of great satisfaction.
Summary of the invention
The object of the present invention is to provide a kind of compound taurine preparation, said preparation has auxiliary protection function to chemical liver injury.
For achieving the above object, the present invention is to be that primary raw material preparation obtains by taurine, glycyrrhizic acid, and the weight proportion of taurine and glycyrrhizic acid is 1:2.
Preparation of the present invention, basic upper at mentioned component, directly or again adds suitable edible or pharmaceutic adjuvant, can make the various dosage forms such as capsule, tablet, granule.The above-mentioned edible or pharmaceutic adjuvant that can add comprises: diluent, suspending agent, disintegrating agent, antioxidant, emulsifying agent, adhesive and antiseptic.
The specific embodiment
Embodiment 1: compound taurine preparation, and its raw material and weight portion are: 50 parts of taurines, 100 parts of glycyrrhizic acids, add appropriate amount of auxiliary materials, make capsule, tablet, granule etc.
Embodiment 2: to CCl
4the protective effect of induced mice chemical liver injury
By tested mice random packet, 10 every group, successive administration 7 days, 1 hour subcutaneous injection 0.5%CCl after last administration
4oil solvent 0.1mg/kg carries out copying of acute hepatic injury model, posterior orbit venous plexus blood sampling in 16 hours, separation of serum, the content of mensuration serum alt, AST.Administration is respectively organized to indicator and model group and do T-test check.
With the comparison of blank group,
#p < 0.05; With model control group comparison,
*p < 0.05
Test shows, each administration group serum AST, ALT value are starkly lower than model control group, and close to blank group, show that preparation of the present invention has auxiliary protection function to chemical liver injury, and there is effective fast, short treating period, the feature such as cost is low, side effect is little.
Claims (2)
1. a compound taurine preparation, is characterized by: it is to be that primary raw material preparation obtains by taurine, glycyrrhizic acid.
2. a kind of compound taurine preparation according to claim 1, is characterized by: the weight proportion of taurine and glycyrrhizic acid is 1:2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310534597.3A CN103550236A (en) | 2013-10-26 | 2013-10-26 | Compound taurine preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310534597.3A CN103550236A (en) | 2013-10-26 | 2013-10-26 | Compound taurine preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103550236A true CN103550236A (en) | 2014-02-05 |
Family
ID=50004710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310534597.3A Pending CN103550236A (en) | 2013-10-26 | 2013-10-26 | Compound taurine preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103550236A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1448497A (en) * | 2002-03-28 | 2003-10-15 | 庄玉坤 | Alcoholic beverage capable of reducing hepatic injury or noninjuring liver |
CN1634587A (en) * | 2004-12-06 | 2005-07-06 | 北京阜康仁生物制药科技有限公司 | Compound preparation for treating urgent and chronic liver diseases and its preparation method |
CN1827093A (en) * | 2005-04-29 | 2006-09-06 | 四川三民药业有限公司 | Taurine injection and method for preparing the same |
CN101757016A (en) * | 2010-01-06 | 2010-06-30 | 吴昌蔚 | Medicine composition for treating flu and preparation method thereof |
-
2013
- 2013-10-26 CN CN201310534597.3A patent/CN103550236A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1448497A (en) * | 2002-03-28 | 2003-10-15 | 庄玉坤 | Alcoholic beverage capable of reducing hepatic injury or noninjuring liver |
CN1634587A (en) * | 2004-12-06 | 2005-07-06 | 北京阜康仁生物制药科技有限公司 | Compound preparation for treating urgent and chronic liver diseases and its preparation method |
CN1827093A (en) * | 2005-04-29 | 2006-09-06 | 四川三民药业有限公司 | Taurine injection and method for preparing the same |
CN101757016A (en) * | 2010-01-06 | 2010-06-30 | 吴昌蔚 | Medicine composition for treating flu and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
高长梅等: "中西药物治疗肝纤维化的进展", 《职业与健康》, vol. 28, no. 7, 30 April 2012 (2012-04-30), pages 877 - 878 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103393911A (en) | Drug for treating beriberi | |
CN103330865B (en) | Medicine for curing non-alcoholic steatohepatitis and preparation method thereof | |
CN102552512B (en) | Traditional Chinese medicine used for treating hepatitis B | |
CN101357184A (en) | Chinese traditional medicine for treating hepatosis and preparation method thereof | |
CN103519185A (en) | Health care product for preventing and treating chemical liver injury | |
CN103520148A (en) | Preparation for auxiliary protection against chemical liver injury | |
CN103520191A (en) | Schisandra chinensis dl-tetrahydropalmatine preparation | |
CN103536614A (en) | Composition containing soybean phospholipid | |
CN104435977A (en) | Medicine for treating liver injuries and preparation method of medicine | |
CN103550236A (en) | Compound taurine preparation | |
CN103550235A (en) | Preparation for preventing or treating liver injury | |
CN103550202A (en) | Compound preparation | |
CN103550199A (en) | Compound preparation | |
CN103479835A (en) | Traditional Chinese medicine for treating liver cirrhosis | |
CN103520149A (en) | Preparation for auxiliary protection against chemical liver injury | |
CN103550234A (en) | Compound oleanolic acid preparation | |
CN103494823A (en) | Preparation for preventing or treating liver injury | |
CN103536590A (en) | Compound preparation | |
CN103550201A (en) | Schisandra chinensis preparation | |
CN103463557A (en) | Chinese medicinal formula for treating hepatitis B | |
CN103550238A (en) | Composition containing procyanidine | |
CN103550239A (en) | Composition for treating liver injury | |
CN103494830A (en) | Composition for treating liver injury | |
CN103519186A (en) | Health food for auxiliary protection against chemical liver injury | |
CN103519183A (en) | Health food for auxiliary protection against chemical liver injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140205 |